Oricell Therapeutics Holding, an innovator in cancer immunotherapy, has announced the successful closing of a USD 70 million Series C1 financing round. The funding will support the company’s global expansion, advance clinical development of its CAR-T cell therapy pipeline and strengthen its technology platforms as it moves towards commercialisation.

The financing round was co-led by Beijing Medical and Health Care Industry Investment Fund, Qiming Venture Partners and a global healthcare fund. Additional participation came from a sovereign wealth fund, c, E-Town Capital, Elikon Venture and Talon Capital. Proceeds from the round will be used to scale clinical trials worldwide and enhance its manufacturing and research capabilities.

The company is developing a differentiated portfolio of CAR-T cell therapies for solid tumours, supported by three proprietary platforms built over the past decade. These include OriAb, an antibody discovery and engineering library; OriArmoring, which enhances T-cell persistence and functional performance across therapeutic areas; and OnGo (Fast) CMC, a rapid, scalable manufacturing platform designed to improve efficiency and reduce production timelines.

Commenting on the funding, Dr. Helen Yang, Chairlady and CEO of Oricell Therapeutics, said the strong investor support reinforces confidence in the company’s science and long-term vision. She noted that Oricell will continue to accelerate global clinical development while advancing in vivo CAR-T products and new technologies. She added that the company’s mission is to deliver effective and affordable cell therapies to cancer patients worldwide and to build a leading global immunotherapy enterprise.

Peng Ren, Chairman and General Manager of Beijing Medical and Health Care Industry Investment Fund, said, “Cell therapy represents a critical frontier in the treatment of solid tumours. The impressive clinical progress of Oricell’s GPC3-targeted CAR-T therapy in HCC and expressed confidence in the company’s R&D strength and commercial strategy.”

The company has generated proof-of-concept clinical data across multiple CAR-T programmes. Its lead candidate, Ori-C101, is an autologous GPC3-targeted CAR-T therapy for advanced HepatoCellular Carcinoma (HCC). Both a Phase I Investigator-Initiated Trial and a Phase I IND study have been completed, demonstrating a strong efficacy and safety profile. The clinical results have been presented at major global conferences, including ASCO 2021 and ASCO 2025. Ori-C101 is now entering a registrational pivotal trial and is positioned to potentially become the world’s first approved CAR-T therapy for HCC.